Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people do see some weight loss in their first month on Wegovy, though the amount varies and the early weeks are primarily about tolerability, not maximum effect. The 0.25mg starting dose is intentionally gentle — your body is adjusting, appetite suppression builds gradually, and meaningful loss typically follows over months, not days. Wegovy (semaglutide) is a prescription-only medicine; a prescriber assesses whether it is clinically appropriate before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Your first pen delivers 0.25mg of semaglutide once a week. This is not the dose at which most people experience significant appetite suppression, it exists to let your digestive system adapt without being overwhelmed. A question our prescribers hear most weeks is some version of: "I've had two injections and I'm not sure it's doing anything, is that normal?" For the majority of people, yes, it is.
The scale may move a little. Some people find they naturally eat slightly less simply because nausea makes large meals unappealing. Others notice almost no change in appetite at all. Nausea, constipation, and mild digestive discomfort are most common in this window and typically ease as the weeks pass, as the NHS's semaglutide medicines page explains. What this fortnight is really doing is laying the groundwork for what comes next.
By weeks three and four, many people begin noticing the first real signals: meals feel satisfying sooner, the pull toward evening snacking quietens, portion sizes shrink naturally. The scale often follows, though not always as dramatically as people hope.
A realistic first-month figure for most people is somewhere between 1 and 3 kg, though this is not a clinical target, it is a rough description of what is commonly reported. Body weight fluctuates day to day with hydration, digestion and sodium intake, which is why weekly weigh-ins at the same time of day give a cleaner picture than daily readings. If you want a fuller account of what these early weeks look like, including the Wegovy first month results that people commonly report, our guide to the first month of Wegovy covers the experience in more detail.
The absence of dramatic loss at this stage does not mean the medicine is not working. It means it is doing exactly what it is designed to do: start gently.
The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. At the 2.4mg maintenance dose, participants lost around 15% of their starting body weight on average, a figure that accumulated over many months, not in the opening weeks. The medicine's full effect builds as the dose titrates upward and the body responds.
This matters because the first month is genuinely not representative of what Wegovy does over time. People who feel underwhelmed by early results and stop treatment early miss the phase where the real work happens. Dose increases occur roughly every four weeks under prescriber guidance; each step tends to bring a deeper reduction in appetite. If you are curious about how the timeline unfolds beyond month one, how long Wegovy takes to work sets out the evidence-based picture clearly.
For context on what the private cost of treatment involves, our treatment overview page sets out everything that is included.
Two people on the same dose, eating similar diets, can lose noticeably different amounts in month one. Several things drive this. Starting weight matters, a higher starting weight tends to produce larger absolute losses even at equivalent percentages. Sleep, stress, physical activity, and any medications that affect weight or fluid retention all play a role. Digestive side effects that reduce food intake early on can temporarily inflate initial figures, then level off as nausea settles.
Those who have previously tried semaglutide and found it less effective the second time may be responding to a different set of factors, there is specific information on Wegovy not working as well on a second course for anyone in that position.
The shape of the first month is also influenced by how closely someone follows the lifestyle advice that accompanies treatment. Adequate protein, regular hydration, and some physical activity all support the medicine's effects and help preserve muscle as weight falls. This is not about being perfect, it is about the cumulative effect of small, consistent changes.
If you want a clearer sense of what outcomes other people have seen by the end of month one, average first-month weight loss on Wegovy pulls together what the data and real-world reports show. And if the first week specifically is on your mind, what happens in the first week on Wegovy addresses that narrower window directly.
Wegovy is a prescription-only medicine. Whether it is right for you depends on a full clinical assessment, not a figure on a website. If you would like to speak with a prescriber and find out whether you are eligible, you are welcome to start your free consultation at any point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.